Actually, an effective inhibition of cancer development and progression has been achieved with strategies devised to rectify a dysfunctional p53 pathway, particularly due to MDM2 and MDMX overexpression (Hong et al., 2014; Li and Lozano, 2013; Wade et al., 2013). Here, TP53 is linked to cancer.